Back to Search
Start Over
Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
- Source :
-
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2016 Jul; Vol. 78 (1), pp. 199-207. Date of Electronic Publication: 2016 Jun 11. - Publication Year :
- 2016
-
Abstract
- Purpose: Natural killer (NK) cells are well known to be the most important effector cells mediating antibody-dependent cellular cytotoxicity (ADCC) which is an important mechanism of action of antibody drugs. We evaluated the effects of chemotherapy on the cell number and activity of NK cells from patients who received the vincristine-cyclophosphamide-doxorubicin-prednisone (VCAP), doxorubicin-ranimustine-prednisone (AMP), and vindesine-etoposide-carboplatin-prednisone (VECP) (mLSG15) or mLSG15-like (-L) regimen, which is one of the standard of cares for newly diagnosed adult T-cell leukemia-lymphoma (ATL), or the cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) or CHOP-L regimen which is another standard of care for ATL and peripheral T-cell lymphoma (PTCL).<br />Methods: The number of lymphocytes and NK cells, and NK cell activity, were assessed using flow cytometry and a (51)Cr release assay, respectively.<br />Results: A total of 26 patients with untreated ATL or PTCL were enrolled, and blood samples from 25 patients were evaluable. NK cell number in ATL decreased after mLSG15/-L treatment, and the degree of decrease in the NK cell number was more prominent just before VECP therapy (Day 15-17 of each cycle) than just before VCAP therapy (Day 1 of each cycle). The NK cell number in ATL after CHOP/-L treatment also decreased. Interestingly, the NK cell activity showed a tendency to increase after the treatment. NK cell number in PTCL did not decrease by CHOP/-L regimen, but the activity was slightly decreased after the treatment.<br />Conclusions: These results indicate that the effects of chemotherapeutic agents on NK cells vary according to the disease type and intensity of chemotherapy.
- Subjects :
- Adult
Aged
Antineoplastic Combined Chemotherapy Protocols administration & dosage
Antineoplastic Combined Chemotherapy Protocols pharmacology
Carboplatin administration & dosage
Case-Control Studies
Cyclophosphamide administration & dosage
Cyclophosphamide pharmacology
Cyclophosphamide therapeutic use
Doxorubicin administration & dosage
Doxorubicin pharmacology
Doxorubicin therapeutic use
Etoposide administration & dosage
Female
Flow Cytometry
Humans
Killer Cells, Natural metabolism
Leukemia-Lymphoma, Adult T-Cell pathology
Lymphoma, T-Cell, Peripheral pathology
Male
Middle Aged
Nitrosourea Compounds administration & dosage
Prednisone administration & dosage
Prednisone pharmacology
Prednisone therapeutic use
Vincristine administration & dosage
Vincristine pharmacology
Vincristine therapeutic use
Vindesine administration & dosage
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Killer Cells, Natural drug effects
Leukemia-Lymphoma, Adult T-Cell drug therapy
Lymphoma, T-Cell, Peripheral drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1432-0843
- Volume :
- 78
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Cancer chemotherapy and pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 27289375
- Full Text :
- https://doi.org/10.1007/s00280-016-3070-2